Beam Therapeutics 3Q 2026: Revenue $307K, Net loss $134.4M, EPS $(1.28) — 10-Q Summary
Beam Therapeutics reported 3Q 2026 revenue of $307K, down 96.8% YoY, and a net loss of $134.4M, or $1.28 per share, wider than the prior-year quarter. The company completed BEACON dosing for risto-cel and may file a biologics license application by year-end. It also advanced BEAM-302 and BEAM-301 in clinical studies and cleared BEAM-304 for development.
How this was made
The 30-second read
Why it matters
The financial print provides a direct, decision-relevant datapoint on burn and operating trajectory, while the clinical updates may influence future catalyst expectations but do not replace the immediate earnings power problem.
Market read
Traders can reassess near-term risk (loss trajectory) and medium-term optionality (trial enrollment status and FDA clearance) based on the newly filed quarter.
What to watch
The summary does not include cash balance, guidance, or dilution risk details; those could dominate near-term trading more than the headline trial milestones.
Background
The piece summarizes Beam Therapeutics’ 3Q 2026 10-Q, combining financial results with multiple hematology program updates (BEACON/risto-cel, BEAM-302, BEAM-301, and BEAM-304).
Ticker impact
Beam reports 3Q 2026 revenue of $307K and a widened net loss, plus clinical updates including complete BEACON dosing and FDA clearance for BEAM-304.
Likely downward pressure or volatility as investors weigh worsening financials against incremental trial progress and the BEAM-304 FDA clearance timeline.
The article discloses a fresh quarterly financial print with large YoY revenue decline and a wider loss, while clinical items are progress updates without approval or commercialization.
Market effects
Reinforces the high burn and low near-term revenue profile typical of gene/hematology biotech, while highlighting that FDA clearances and dosing completion can partially offset sentiment.
No clear regional macro linkage beyond general US biotech risk appetite.
Limited, as the news is company-specific clinical and financial reporting.
Counterpoint
Clinical progress (BEACON dosing completion, durable fetal hemoglobin, and FDA clearance for BEAM-304) could improve probability-weighted outcomes, even as revenue remains negligible.
Key entities
- companyBeam Therapeutics
US-listed biotech issuer reporting 3Q 2026 revenue, net loss, and multiple clinical program milestones plus an FDA clearance for BEAM-304.
